Physician profile
Sheldon E Jordan
NPI 1316941305
$32,125.40
in general payments reported to CMS, 2019-2025
100 companies · $5,561 in 2025
The $5,561 reported for 2025 was more than what 91% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,972 · 2020: $3,978 · 2021: $4,067 · 2022: $4,347 · 2023: $4,930 · 2024: $5,272 · 2025: $5,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $82.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,680.44 |
| Education | $82.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,037.71 | 2021-2025 | |
| Csl Behring | $1,817.06 | 2019-2025 | Hizentra |
| Lundbeck LLC | $1,544.83 | 2019-2025 | Rexulti, Vyepti |
| Teva Pharmaceuticals USA, INC. | $1,522.15 | 2019-2024 | Austedo Xr, Austedo |
| Lilly USA, LLC | $1,375.47 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Novartis Pharmaceuticals Corporation | $1,167.55 | 2019-2025 | |
| Merz Pharmaceuticals, LLC | $1,006.68 | 2021-2025 | Xeomin, Inbrija |
| Ucb, INC. | $994.68 | 2019-2025 | Zilbrysq, Nayzilam, Briviact |
| Amgen INC. | $839.66 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $803.92 | 2019-2025 | Ultomiris, Soliris |
| Pfizer INC. | $784.64 | 2021-2025 | |
| Genentech USA, INC. | $763.39 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Takeda Pharmaceuticals U.S.A., INC. | $761.22 | 2019-2025 | Hyqvia, Trintellix, Gammagard |
| Jazz Pharmaceuticals INC. | $733.71 | 2019-2025 | |
| Biogen, INC. | $672.49 | 2020-2025 | Vumerity, Leqembi, Tysabri |
Show all 100 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.